Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Zinc finger protein 462 is a large, nuclear **transcription factor** belonging to the C2H2-type zinc finger protein family[1][4]. It is involved in **regulation of gene expression by binding DNA and organizing chromatin structure**, which is essential for proper embryonic development, especially of neural and craniofacial tissues. Mutations in ZNF462 are causative for **Weiss-Kruszka syndrome**, an autosomal dominant, neurodevelopmental disorder marked by developmental delay, intellectual disability, hypotonia, distinct craniofacial features, and other congenital anomalies. The protein plays roles in **pluripotency and differentiation of embryonic stem cells, neuronal differentiation**, and may interact with other chromatin modifiers (such as ASXL2). ZNF462 is essential for early developmental processes, and mouse models show that complete loss is embryonic lethal, underscoring its fundamental role in gene regulation during development[1][4][5][6]. **No drugs are currently known to target ZNF462, and it is not classified as a druggable therapeutic target or receptor.**
Not applicable for drugs (no drugs known to target ZNF462 directly)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Zinc finger protein 462 (ZNF462).